MAP2K7 and breast carcinoma: Additionally, PI3K, MEK, p38 and cyclin D1 activation has been described as result of TIMP1 activity in different breast cancer cells, including MDA-MB-231 [20,47], providing the molecular basis mediating the proliferation inhibition observed in our experimental models.